SBIR-STTR Award

Development of Innovative Medical Device Technology for Quantifying Forces during Soft Tissue Manipulation Assessment and Intervention
Award last edited on: 1/24/2022

Sponsored Program
STTR
Awarding Agency
NIH : NCCIH
Total Award Amount
$256,129
Award Phase
1
Solicitation Topic Code
213
Principal Investigator
Mary Terry Loghmani

Company Information

Health Smart Technologies Inc

8349 Union Chapel Road
Indianapolis, IN 46240

Research Institution

----------

Phase I

Contract Number: 1R41AT011494-01
Start Date: 4/1/2021    Completed: 3/31/2022
Phase I year
2021
Phase I Amount
$256,129
The lack of a means to quantify soft tissue manipulation (STM) motion and dose as delivered in the clinic is a critical problem in the reproducibility and therapeutic potential of this non-invasive and non-pharmacological modality. STM is a form of manual therapy used to evaluate and treat musculoskeletal pain, inflammation, and dysfunction. Different soft tissue forces have differing biological effects and outcomes. Evidence suggests STM may serve as a surrogate or augment to exercise, which has important implications in rehabilitation. Like exercise, objective parameters are needed for optimal STM dosing. However, initial research indicates a high level of inconsistency in STM force application, both within and between therapists, while quantitative feedback significantly improves its accuracy and consistency. Unfortunately, current STM practice relies mostly on subjective treatment variables and vague descriptors of soft tissue quality and pain. Unwarranted variation in assessment and treatment can compromise outcomes and diminish the value of the practice. There is a strong need for technology that can generate STM metrics to improve practice by providing a common language to optimize STM examination and intervention, enable dose prescriptions, facilitate training, study its effects, and evaluate outcomes.Our team has developed a novel medical device system, Quantifiable Soft Tissue Manipulation (QSTM™) as a solution to address this void in manual therapy. QSTM™ includes a device (Q1) for the application and sensing of localized forces in smaller regions (e.g., finger or elbow) and another device (Q2) for dispersive forces in larger regions (e.g., back or thigh), along with custom software for recording and analysis of treatment data, including STM force magnitude, angle, rate, and direction. The primary purpose of this proposal is to demonstrate the feasibility of QSTM™ for clinical use. The central hypothesis is that QSTM™ will improve the reproducibility of STM examination and intervention. Project objectives aim to optimize the design of the device system; quantitatively characterize basic STM stroke motion patterns; test the reliability of STM force application using QSTM™ data output; and determine its usability for pain assessment. A large market exists for use of QSTM™ in multiple health disciplines, sports, education, research, and veterinary medicine. People and payers seeking precise, patient-centric care will eventually drive the market. QSTM™ represents a significant improvement over its competition of traditional manual methods, with or without rigid instruments, or mimetic devices. QSTM™ offers an alternative or complement to other approaches. We have consulted with experts on our business model and marketing and sales strategies. This project aligns with the National Center of Complementary and Integrative Health priorities. NIH support will accelerate commercialization. QSTM™ is to manual therapy what the Fitbit is to exercise. QSTM™ better enables individualized rehabilitation through objective measures and goal setting, recording, monitoring, and reproducibility. This progressive technology will integrate patient feedback and clinician perception with quantitative metrics, creating a positive shift to the digital era of soft tissue manual therapy practice. Public Health Relevance Statement PROJECT NARRATIVE The lack of a means to quantify soft tissue manipulation (STM), a form of manual therapy, is a critical barrier to the reproducibility and optimization of this non-invasive and non-pharmacological modality in the management of acute and chronic musculoskeletal pain, inflammation, and injury. Health Smart Technologies, Inc. has developed a novel quantifiable soft tissue manipulation (QSTM™) device system for the manual application and measurement of localized and dispersive forces, addressing the need for objective metrics in connectivity with patient feedback and clinician perception, aimed to improve STM clinical assessment and treatment, training, and research. This STTR Phase I project objectives are to optimize the design of QSTM™ device system, characterize STM stroke patterns with quantitative parameters, test the reliability of targeted STM force application, and evaluate the usability of this technology for pain assessment, moving the field into the digital era of soft tissue manual therapy.

Project Terms:
Affect ; Back ; Dorsum ; Biomechanics ; biomechanical ; Clinical Trials ; Complement ; Complement Proteins ; Edema ; Dropsy ; Hydrops ; Elbow ; Exercise ; Feedback ; Fingers ; Goals ; Health ; Health Priorities ; Industry ; Inflammation ; Intervention Studies ; intervention research ; interventional research ; interventional study ; interventions research ; Language ; Lead ; Pb element ; heavy metal Pb ; heavy metal lead ; Manuals ; Marketing ; Massage ; massage therapy ; Medical Device ; Methods ; Motion ; Musculoskeletal Pain ; United States National Institutes of Health ; NIH ; National Institutes of Health ; Occupations ; Jobs ; Professional Positions ; osteopath ; Pain ; Painful ; Pain Measurement ; Analgesia Tests ; Nociception Tests ; Pain Assessment ; pain assay ; Patients ; Perception ; Physicians ; pressure ; Rehabilitation therapy ; Medical Rehabilitation ; Rehabilitation ; rehab therapy ; rehabilitative ; rehabilitative therapy ; Research ; Research Personnel ; Investigators ; Researchers ; Rheumatism ; Musculoskeletal Pain Disorder ; Rheumatic Diseases ; Rheumatologic Disorder ; Sales ; Computer software ; Software ; Sports ; Standardization ; Stroke ; Apoplexy ; Brain Vascular Accident ; Cerebral Stroke ; Cerebrovascular Apoplexy ; Cerebrovascular Stroke ; brain attack ; cerebral vascular accident ; cerebrovascular accident ; Technology ; Telephone ; Phone ; Testing ; Thigh structure ; Thigh ; Tissues ; Body Tissues ; Veterinary Medicine ; Measures ; Businesses ; Device Designs ; Caring ; Custom ; Pain Threshold ; Pain Tolerance Level ; pain tolerance ; Injury ; injuries ; improved ; Area ; Acute ; Clinical ; Phase ; Variant ; Variation ; Biological ; Evaluation ; Training ; soft tissue ; Discipline ; Measurement ; Veterinarians ; Functional disorder ; Dysfunction ; Physiopathology ; pathophysiology ; Descriptor ; Therapeutic ; Chiropractor ; instrument ; Knowledge ; mechanical ; Mechanics ; Clinic ; Pattern ; System ; Outcome Study ; interest ; Consult ; innovative technologies ; novel ; Modality ; Devices ; Modeling ; response ; Intervention Strategies ; interventional strategy ; Intervention ; Documentation ; mimetics ; Manipulation Therapy ; manual therapy ; Manipulative Therapies ; Cell Phone ; Cellular Telephone ; iPhone ; smart phone ; smartphone ; Cellular Phone ; Provider ; Effectiveness ; Address ; Dose ; Athletic ; Data ; Reproducibility ; Clinical Treatment ; trial regimen ; trial treatment ; Small Business Technology Transfer Research ; STTR ; Monitor ; Development ; developmental ; Output ; injured ; digital ; software systems ; design ; designing ; Clinical assessments ; Integrative Medicine ; integrative healing ; integrative health ; functional outcomes ; Outcome ; Population ; aged ; innovation ; innovate ; innovative ; usability ; compare effectiveness ; commercialization ; phase II trial ; phase 2 trial ; education research ; fitbit ; physical therapist ; physiotherapist ; data access ; chronic musculoskeletal pain ; chronic MSK pain ; Complementary Health ; Visualization ;

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----